ABVX vs. HCM, PBH, ARWR, FOLD, MRUS, BHVN, IDYA, PTCT, XENE, and DYN
Should you be buying ABIVAX Société Anonyme stock or one of its competitors? The main competitors of ABIVAX Société Anonyme include HUTCHMED (HCM), Prestige Consumer Healthcare (PBH), Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), Merus (MRUS), Biohaven (BHVN), IDEAYA Biosciences (IDYA), PTC Therapeutics (PTCT), Xenon Pharmaceuticals (XENE), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry.
HUTCHMED (NASDAQ:HCM) and ABIVAX Société Anonyme (NASDAQ:ABVX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership.
HUTCHMED has higher revenue and earnings than ABIVAX Société Anonyme.
8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 47.9% of ABIVAX Société Anonyme shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
HUTCHMED received 308 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 71.43% of users gave ABIVAX Société Anonyme an outperform vote while only 66.60% of users gave HUTCHMED an outperform vote.
In the previous week, HUTCHMED had 3 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 5 mentions for HUTCHMED and 2 mentions for ABIVAX Société Anonyme. ABIVAX Société Anonyme's average media sentiment score of 1.01 beat HUTCHMED's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.
HUTCHMED currently has a consensus price target of $29.70, suggesting a potential upside of 67.23%. ABIVAX Société Anonyme has a consensus price target of $34.20, suggesting a potential upside of 139.24%. Given HUTCHMED's stronger consensus rating and higher probable upside, analysts plainly believe ABIVAX Société Anonyme is more favorable than HUTCHMED.
Summary
HUTCHMED and ABIVAX Société Anonyme tied by winning 5 of the 10 factors compared between the two stocks.
Get ABIVAX Société Anonyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABIVAX Société Anonyme Competitors List
Related Companies and Tools
